Heterocyclic kinase inhibitors and uses thereof

US12172993B2 · kind B2 · utility

Assignee

• IOMX THERAPEUTICS AG · DE

Inventors

• Peter Sennhenn · Munich, DE
• Sebastian Meier-Ewert · Martinsried, DE
• Nisit Khandelwal · Heidelberg, DE
• David BANCROFT · Gilching, DE

Key dates

• Filing date: Oct 22, 2019
• Grant date: Dec 24, 2024
• Expiry date: Dec 14, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.